Shots:

• The P-III BLISS-LN study involves assessing of IV belimumab 10 mg/kg + standard therapy vs PBO in 448 patients with active lupus nephritis for 104 wks.
• P-III BLISS-LN study results: met 1EPs and all major 2EP; Primary Efficacy Renal Response (PERR) (43% vs 32%); showed consistent safety results; ORR was defined as complete  
• Benlysta is a mAb and a BLyS-specific inhibitor designed for binding to soluble BLyS further inhibiting the survival of B cells. The company plans for regulatory submissions based on P-III results in H1’2020

Click here to read full press release/ article

Ref: PRNewswire | Image: GSK